IRVINE, Calif.—Allergan (NYSE: AGN) saw its sales of eyecare pharmaceuticals increase by 25.1 percent (up 20.5 percent at constant currency rates), to $539.6 million, in this year’s second quarter.
The company’s total net product sales reached nearly $1.6 billion, a gain of 20.1 percent (up 15.7 percent at constant currency rates), in Q2.
In the first six months of 2008, Allergan’s sales of eyecare pharmaceuticals were $1,031.8 million, a 23.7 percent increase (up 19 percent at constant currency rates).
Total product sales in the period rose 21.5 percent (up 17 percent at constant currency rates) to $2.2 billion.
July 2008
Financial
